Stock Track | Nurix Therapeutics Soars 5.90% in Intraday Trading on Positive Analyst Ratings

Stock Track
01/29

Nurix Therapeutics' stock surged 5.90% during intraday trading on Thursday, reflecting strong investor confidence in the biotechnology company.

The price increase follows a series of positive analyst actions, including price target raises and maintained buy ratings from multiple firms. H.C. Wainwright increased its target price to $32 from $31, Stifel raised its target to $35 from $33, and RBC lifted its target to $30 from $28, all while maintaining bullish ratings. Additionally, Wells Fargo maintained an Overweight rating and BTIG sustained its positive outlook with a $30 price target.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10